aspartic acid has been researched along with Osteoporosis in 7 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoporosis is a progressive systemic skeletal disease, in which the equilibrium of bone resorption and bone formation is disturbed." | 1.40 | Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis? ( Cai, K; Dong, Y; Hu, X; Jin, Y; Liu, J; Ma, J; Wu, G; Zhang, H, 2014) |
| " The oral and nasal bioavailability after p." | 1.33 | Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol. ( Miyamoto, K; Nishioka, T; Sakura, N; Toshima, K; Yamoto, K; Yokogawa, K, 2006) |
| " Modification of the beta-alanine 3-substituents alters the potency and physicochemical properties of these receptor antagonists and in some cases provides orally bioavailable alpha(v)beta(3) inhibitors." | 1.31 | Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements. ( Askew, BC; Brashear, KM; Breslin, MJ; Coleman, PJ; Duggan, ME; Fernandez-Metzler, C; Hartman, GD; Hoffman, WF; Hunt, CA; Hutchinson, JH; Leu, CT; Libby, LA; Lynch, JJ; Lynch, R; Ma, B; McVean, CA; Merkle, KM; Prueksaritanont, T; Rodan, GA; Rodan, SB; Stump, GL; Wallace, AA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CW | 1 |
| Lee, CY | 1 |
| Lin, SY | 1 |
| Kang, L | 1 |
| Fu, YC | 1 |
| Chen, CH | 1 |
| Wang, CK | 1 |
| Liu, Y | 1 |
| Yu, P | 1 |
| Peng, X | 1 |
| Huang, Q | 1 |
| Ding, M | 1 |
| Chen, Y | 1 |
| Jin, R | 1 |
| Xie, J | 1 |
| Zhao, C | 1 |
| Li, J | 1 |
| Liu, J | 1 |
| Zhang, H | 1 |
| Dong, Y | 1 |
| Jin, Y | 1 |
| Hu, X | 1 |
| Cai, K | 1 |
| Ma, J | 1 |
| Wu, G | 1 |
| ISHIGAMI, H | 1 |
| Yokogawa, K | 1 |
| Toshima, K | 1 |
| Yamoto, K | 1 |
| Nishioka, T | 1 |
| Sakura, N | 1 |
| Miyamoto, K | 1 |
| Kwak, CS | 1 |
| Kang, CM | 1 |
| Kang, HS | 1 |
| Song, KY | 1 |
| Lee, MS | 1 |
| Seong, SC | 1 |
| Park, SC | 1 |
| Coleman, PJ | 1 |
| Brashear, KM | 1 |
| Hunt, CA | 1 |
| Hoffman, WF | 1 |
| Hutchinson, JH | 1 |
| Breslin, MJ | 1 |
| McVean, CA | 1 |
| Askew, BC | 1 |
| Hartman, GD | 1 |
| Rodan, SB | 1 |
| Rodan, GA | 1 |
| Leu, CT | 1 |
| Prueksaritanont, T | 1 |
| Fernandez-Metzler, C | 1 |
| Ma, B | 1 |
| Libby, LA | 1 |
| Merkle, KM | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Lynch, JJ | 1 |
| Lynch, R | 1 |
| Duggan, ME | 1 |
7 other studies available for aspartic acid and Osteoporosis
| Article | Year |
|---|---|
Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)
Topics: Animals; Aspartic Acid; Biopolymers; Bone and Bones; Gold; Lipids; Minerals; Nanoparticles; Osteopor | 2022 |
Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
Topics: Animals; Aspartic Acid; Bone and Bones; Bone Density Conservation Agents; Calcitonin; Drug Delivery | 2019 |
Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
Topics: Anabolic Agents; Animals; Aspartic Acid; Bone and Bones; Bone Density Conservation Agents; Bone Remo | 2014 |
[EXPERIMENTAL STUDY ON OSTEOPOROSIS USING RI].
Topics: Amino Acids; Aspartic Acid; Calcium Isotopes; Glycine; Metabolism; Mice; Osteoporosis; Proline; Rese | 1964 |
Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol.
Topics: Administration, Intranasal; Animals; Aspartic Acid; beta-Cyclodextrins; Bone and Bones; Dose-Respons | 2006 |
Dehydroepiandrosterone-dependent induction of peroxisomal proliferation can be reduced by aspartyl esterification without attenuation of inhibitory bone loss in ovariectomy animal model.
Topics: Acyl-CoA Dehydrogenase; Adjuvants, Immunologic; Animals; Aspartic Acid; Biomarkers; Calcium; Cholest | 2000 |
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
Topics: Amino Acids; Animals; Aspartic Acid; Binding, Competitive; Dogs; Drug Evaluation, Preclinical; Human | 2002 |